Search

Your search keyword '"Kralova K"' showing total 88 results

Search Constraints

Start Over You searched for: Author "Kralova K" Remove constraint Author: "Kralova K"
88 results on '"Kralova K"'

Search Results

2. S285: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 2-YEAR FOLLOW-UP FROM THE CARDINAL STUDY

3. P1538: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK WASHOUT PERIOD IN PHASE 3 CARDINAL STUDY (NCT03347396)

4. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

5. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

6. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

27. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

28. Comprehensive spectroscopic, metabolomic, and proteomic liquid biopsy in the diagnostics of hepatocellular carcinoma.

29. Raman spectroscopy and Raman optical activity of blood plasma for differential diagnosis of gastrointestinal cancers.

30. Comparative study of Raman spectroscopy techniques in blood plasma-based clinical diagnostics: A demonstration on Alzheimer's disease.

31. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.

32. Quality of MedDRA ® Coding in a Sample of COVID-19 Vaccine Medication Error Data.

33. Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy.

34. Anticancer Applications of Essential Oils Formulated into Lipid-Based Delivery Nanosystems.

35. Advances in Biologically Applicable Graphene-Based 2D Nanomaterials.

36. Advances in Nanostructures for Antimicrobial Therapy.

37. Advances in Drug Delivery Nanosystems Using Graphene-Based Materials and Carbon Nanotubes.

38. Potential of Nanonutraceuticals in Increasing Immunity.

39. Potential of Nanomaterial Applications in Dietary Supplements and Foods for Special Medical Purposes.

40. Halogenated 1-Hydroxynaphthalene-2-Carboxanilides Affecting Photosynthetic Electron Transport in Photosystem II.

41. Photosynthesis-Inhibiting Activity of 1-[(2-Chlorophenyl)carbamoyl]- and 1-[(2-Nitrophenyl)carbamoyl]naphthalen-2-yl Alkylcarbamates.

42. Antimycobacterial N-alkoxyphenylhydroxynaphthalenecarboxamides affecting photosystem II.

43. Ring-substituted 8-hydroxyquinoline-2-carboxanilides as photosystem II inhibitors.

44. Ring-substituted 8-hydroxyquinoline-2-carboxanilides as potential antimycobacterial agents.

45. Synthesis and Biological Evaluation of N-Alkoxyphenyl-3-hydroxynaphthalene-2-carboxanilides.

46. Synthesis and Biological Evaluation of N-Alkyl-3-(alkylamino)-pyrazine-2-carboxamides.

47. Synthesis and antimycobacterial properties of ring-substituted 6-hydroxynaphthalene-2-carboxanilides.

48. Structure-activity relationships of N-benzylsalicylamides for inhibition of photosynthetic electron transport.

49. Preparation and biological properties of ring-substituted naphthalene-1-carboxanilides.

50. New potentially active pyrazinamide derivatives synthesized under microwave conditions.

Catalog

Books, media, physical & digital resources